Explore
Validate
Learn
Flow cytometry
Blocking/NeutralizingAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 16-9927-82 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD253 (TRAIL) Monoclonal Antibody (RIK-2), Functional Grade, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The RIK-2 monoclonal antibody reacts with human TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily. TRAIL is not expressed by resting human cells but has been shown to be induced under certain activation conditions. Iin addition it is expressed on several human tumor lines. Interaction of TRAIL with its ligand, Apo-2, induces apoptosis. RIK-2 blocks TRAIL-induced apoptosis. Applications Reported: The RIK-2 antibody has been reported for use in flow cytometric analysis. It has also been reported in blocking of TRAIL in functional assays. Applications Tested: The RIK-2 antibody has been tested for blocking of staining with fluorochrome conjugated RIK-2 in flow cytometric analysis of human TRAIL transfected cells. This can be used at less than or equal to 1 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Storage and handling: Use in a sterile environment. Filtration: 0.2 µm post-manufacturing filtered. Purity: Greater than 90%, as determined by SDS-PAGE. Endotoxin Level: Less than 0.001 ng/µg antibody, as determined by LAL assay. Aggregation: Less than 10%, as determined by HPLC.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- RIK-2
- Vial size
- 100 µg
- Concentration
- 1 mg/mL
- Storage
- 4° C
Submitted references Canonical TGF-β Signaling Pathway Represses Human NK Cell Metabolism.
MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.
Dengue virus activates membrane TRAIL relocalization and IFN-α production by human plasmacytoid dendritic cells in vitro and in vivo.
TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis.
Bystander macrophage apoptosis after Mycobacterium tuberculosis H37Ra infection.
HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha.
Anti-HIV state but not apoptosis depends on IFN signature in CD4+ T cells.
Zaiatz-Bittencourt V, Finlay DK, Gardiner CM
Journal of immunology (Baltimore, Md. : 1950) 2018 Jun 15;200(12):3934-3941
Journal of immunology (Baltimore, Md. : 1950) 2018 Jun 15;200(12):3934-3941
MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.
Turner A, Li LC, Pilli T, Qian L, Wiley EL, Setty S, Christov K, Ganesh L, Maker AV, Li P, Kanteti P, Das Gupta TK, Prabhakar BS
PloS one 2013;8(2):e56817
PloS one 2013;8(2):e56817
Dengue virus activates membrane TRAIL relocalization and IFN-α production by human plasmacytoid dendritic cells in vitro and in vivo.
Gandini M, Gras C, Azeredo EL, Pinto LM, Smith N, Despres P, da Cunha RV, de Souza LJ, Kubelka CF, Herbeuval JP
PLoS neglected tropical diseases 2013;7(6):e2257
PLoS neglected tropical diseases 2013;7(6):e2257
TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis.
Bisgin A, Terzioglu E, Aydin C, Yoldas B, Yazisiz V, Balci N, Bagci H, Gorczynski RM, Akdis CA, Sanlioglu S
BMC musculoskeletal disorders 2010 Aug 27;11:192
BMC musculoskeletal disorders 2010 Aug 27;11:192
Bystander macrophage apoptosis after Mycobacterium tuberculosis H37Ra infection.
Kelly DM, ten Bokum AM, O'Leary SM, O'Sullivan MP, Keane J
Infection and immunity 2008 Jan;76(1):351-60
Infection and immunity 2008 Jan;76(1):351-60
HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha.
Hardy AW, Graham DR, Shearer GM, Herbeuval JP
Proceedings of the National Academy of Sciences of the United States of America 2007 Oct 30;104(44):17453-8
Proceedings of the National Academy of Sciences of the United States of America 2007 Oct 30;104(44):17453-8
Anti-HIV state but not apoptosis depends on IFN signature in CD4+ T cells.
Audigé A, Urosevic M, Schlaepfer E, Walker R, Powell D, Hallenberger S, Joller H, Simon HU, Dummer R, Speck RF
Journal of immunology (Baltimore, Md. : 1950) 2006 Nov 1;177(9):6227-37
Journal of immunology (Baltimore, Md. : 1950) 2006 Nov 1;177(9):6227-37
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of human Trail transfected cells with Anti-Human CD253 (TRAIL) PE. Appropriate isotype controls were used (open histogram). Total viable cells were used for analysis.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 TRAIL and its receptor (both death and decoy) expression profile on CD4 + T cells . A scattered dot plot profile of TRAIL and its receptors is provided in Panel A . Solid circles indicate RA patients while dots represent control individuals. Error bars display mean (+-) SEM. Representative flow cytometric analyses of a control individual (upper panels) and an RA patient (lower panels) are shown in Panel B , while Panel C shows the relative increase in TRAIL and its receptors on CD4 + T cells of RA patients compared to controls.
